Although the present short-term treatment with 3K3A-APC did not improve broken BBB in the non-ischemic contralateral hemisphere in Pdgfrb + ⁣/− mice, it remains to be seen whether longer time therapeutic regimens with 3K3A-APC, as used, for example, in ALS (Zhong, 2009) and AD (Lazic et al., 2019) models, would alleviate BBB breakdown in Pdgfrb + ⁣/− mice that are not challenged by stroke. This evidence concerns the gene PDGFRB and Alzheimer disease.